BioAtla sought discussion with the FDA regarding the Phase 3 clinical trial design on August 8, 2025.
1 report, 1 independent
Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioAtla sought discussion with the FDA regarding the Phase 3 clinical trial design on August 8, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- SynAct Pharma AB is seeking discussion with the FDA regarding the design of its Phase 3 clinical trials.
- FDA placed a clinical hold on Phase 2/3 trials for SK Biopharm on September 1, 2026.
- TELIX Pharmaceuticals is conducting Phase 3 trials and seeking alignment on the New Drug Application pathway with the FDA.
- The FDA granted Safe to Proceed for the Pivotal Phase 3 study of Vivace Therapeutics, Inc.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
Coverage
Newest first; wire copies grouped- GlobeNewswireBioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosi